Environmental risk assessment of pharmaceuticals at a seasonal holiday destination in the largest freshwater shallow lake in Central Europe

Eva Molnar, Gabor Maasz*, Zsolt Pirger

Adaptive Neuroethology Research Group, Department of Experimental Zoology, Balaton Limnological Institute, MTA Centre for Ecological Research, 8237 Tihany, Hungary

*Correspondence to Dr Gabor Maasz, Adaptive Neuroethology Research Group, Department of Experimental Zoology, Balaton Limnological Institute, MTA Centre for Ecological Research, 8237 Tihany, Hungary

E-mail: maasz.gabor@okologia.mta.hu
Abstract

The presence of pharmacologically active compounds (PhACs) in surface waters poses an environmental risk of chronic exposure to non-target organisms, which is a well-established and serious concern worldwide. Our aim was to determine the temporal changes in ecological risk quotient (RQ) based on the concentrations of 42 PhACs from six sampling sites on seven sampling dates in the water of a freshwater lake in Central Europe preferentially visited by tourists. Our hypothesis was that the environmental risk increases during the summer holiday season due to the influence of tourists. Different experimental toxicological threshold concentrations and seasonal measured environmental concentrations of 16 PhACs were applied to ecological risk assessment. RQs of 4 dominant PhACs (diclofenac, estrone [E1], estradiol [E2], and caffeine) indicated high ecological risk (RQ > 1) for freshwater ecosystems. Additionally, our results confirmed the assumptions that the high tourist season had a significant impact on the calculated RQ, however these results are mainly due to the concentration and temporal change of particular PhACs, including diclofenac (5.3-419.4 ng/L), E1 (0.1-5.5 ng/L), and E2 (0.1-19.6 ng/L). The seasonal dependent highest RQs changed as follows: 9.80 (June 2017; E2), 1.23 (August 2017; E1), 0.43 (November 2017; E1), 0.51 (April 2018; E1), 5.58 (June 2018, diclofenac), 39.50 (August 2018; diclofenac), and 30.60 (October 2018; diclofenac).

Keywords

environmental risk assessment, pharmacologically active compounds, ecotoxicological data, seasonal effects, touristic region, Lake Balaton

Introduction

Medicine has improved considerably in recent decades, contributing to the increase in the average age and fast growth of the human population. At the same time, the consumption of medication has changed significantly (Ginebreda et al. 2010; Guzel et al. 2019), resulted in an increased use of pharmaceuticals. However, waste water treatment (WWT) technologies are not suitable for removing all kind of pharmacologically active compounds (PhACs) with the same efficiency, therefore, a large majority of PhACs with their metabolites and conjugates have been appearing in all environmental compartments (surface waters, sediment, biota) worldwide (Halling-Sorensen et al. 1998; Kummerer 2004).

This is a concern for several reasons (Daughton and Ternes 1999; Diaz-Cruz et al. 2003). Information is lacking about possible harmful effects on non-target freshwater organisms (e.g., zooplankton, molluscs, fish) when different PhACs form a mixture in receiving environments (Guzel et al. 2019). At the same time, it should also be noted that most measurement and risk assessment have been based on individual compound but PhACs never occur as single substances in the environment.
Therefore, to get a realistic picture about ecosystem involvement, investigation and assessment of multi-component mixture effect of PhACs are required (De Zwart and Posthuma 2005; Lin et al. 2018; Heys et al. 2016). Additionally, the correct interpretation of measured environmental concentration (MEC) of PhACs is a big challenge for scientists, even today. Not only is the limited available experimental toxicity data (median effective concentration [EC50], median lethal concentration [LC50], and no observed effect concentration [NOEC]) a problem (Ginebreda et al. 2010; Hernando et al. 2006; la Farre et al. 2008; Thomaidi et al. 2015), but even if such data exist and are accessible, they are usually described based on different observations (e.g., various endpoints and species) so, in other words, they are not consistent (Lange and Dietrich 2002). Of course, this is understandable because different studies of PhACs have been conducted in vivo using different mechanisms, therefore, the effect of the given PhACs have been observed using different endpoints (e.g., growth, mortality, reproduction or developmental, behavioural effects, and molecular, cellular, tissue level changes).

Even though the MEC is known, since there is a lack of standardized experimental toxicity data in many cases (la Farre et al. 2008; Thomaidi et al. 2015), the ecological risk assessment (ERA) cannot be appropriately performed (Ferrari et al. 2004).

To estimate the harmful effect of PhACs on an ecosystem, a risk quotient (RQ) is usually applied, which is defined as the ratio of the maximum MEC to the predicted no effect concentrations (PNEC), where PNEC depends on the available toxicological data (Carlsson et al. 2006; Deo 2014; Ferrari et al. 2004; Hernando et al. 2006; Komori et al. 2013). To get the most realistic ecological RQ values, PNECs need to be derived from species sensitivity distribution (SSD) curve (Posthuma et al. 2002) or at least experimental NOEC, or E(L)C50. Other PNECs estimated based on, for example, ECOSAR (Sanderson et al. 2004) are only used for cases which no laboratory data are available, however, they need to be managed with a high degree of uncertainty.

In other aspect, the degree of risk depends on the concentration data, the forms and migration of PhACs in the environmental elements, and these levels are influenced by among other factors, the efficiency of the WWT technology applied, the resistance of (bio)degradation, complexation, sorption, bioaccumulation, defined daily doses, dosage of medicine (periodical or continuous), and even weather conditions (Andreozzi et al. 2002; Bouissou-Schurtz et al. 2014). Furthermore, for a comprehensive ERA, all environmental elements should be examined because PhACs, depending on the environmental conditions (e.g., temperature, UV radiation), are distributed between different matrices (water, sediment, suspended solid, biofilm) (Dobor et al. 2012). Besides environmental conditions, effect of tourism also needs to be considered for ERA. The improving tourism industry frequently poses a risk to the ecosystems by the increased load of WWT plant locally and many recreational activities (e.g., swimming, sailing, kayaking, canoeing, diving, or fishing), respectively (Hadwen et al. 2005; Katircioglu 2014; Mihalic 2000). Increased PhAC levels, also including recreational substances (e.g., caffeine and illicit drugs), during high tourism season is a well-known phenomenon (Guzel et al. 2019; Lin et al. 2018; Nakada et al. 2017; Zhang et al. 2017) in rivers flowing throughout cities, however, there are only limited data in case of lakes (Maasz et al., 2019).
Based on all them, the production of an accurate and definite assessment of risk level is a very difficult and complex task; however, approximate calculations are also necessary and useful to prevent environmental damage.

This study complements and uses another approach to analyse our earlier screening data resulted from investigating the presence of 134 PhACs in the surface water of Lake Balaton and its catchment area from June 2017 to April 2018. Taking the studied period and sampled sites belonging to the lake into account, 39 PhACs were detected and quantified in water samples from the lake (Maasz et al. 2019). This was the first extended qualitative and quantitative study to present data on the occurrence of PhACs derived from several chemical classes in this lake. Measurements have continued and the database has been complemented with further MEC data from June, August, and October 2018. In total it was possible to consider the ERAs of 42 PhACs. The main goals of the present study were to estimate the environmental risk of single and mixed PhACs in the surface water of Lake Balaton, a popular touristic region in Europe, subsequently, to explore a possible correlation between the magnitude of the actual hazard and impacts of seasonal changes (spring, summer, autumn, winter).

**Experimental methodology**

**Study area**

The study was conducted in Lake Balaton (Fig. 1), which is one of the largest (A: 594 km$^2$, mean depth: 3.2 m, V: ~1.8 km$^3$) freshwater shallow lakes in Central Europe (Hungary) (Istvanovics et al. 2007) and very popular with tourists. The Lake Balaton resort area is an internationally important tourist and recreation centre visited by millions of tourists a year, especially in summer season (Maasz et al. 2019; URL1). The maximum number of guest nights at commercial accommodation in the counties surrounding Lake Balaton approaches ~900,000 in an average summer month (e.g., August) in a high tourist season also in 2017 and 2018, while this value is only ~300,000 in winter (see Supplementary Fig. 1). The human population shows unequal spatio-temporal distribution in this region; two-thirds of the local resident population (~380,000 people) inhabit the near-coastal area of the lake (URL1; URL2). Nowadays, more than 40 WWT plants are being situated in the catchment area of Lake Balaton, the largest one (with a capacity of 50,000 m$^3$/day) can be found in Zalaegerszeg (URL3) which is the largest town of the catchment area (with ~60,000 inhabitants) (URL1). This town is located on the riverbank of River Zala (the largest tributary of Lake Balaton) supplying ~50% of the lake's total surface water input (URL3). Since the waste water effluent reaches directly the River Zala it also plays a potential role in the PhACs pollution of Lake Balaton.

**Sample collection, preparation, and measurement**

Designation of sampling sites (Fig. 1) was based on our previous study (Maasz et al. 2019) and the current research may be considered to be the continuation of that work. Forty-two water samples used for the present study were collected in June, August, and November of 2017, and April, June, August,
and October of 2018 from six sampling sites on the littoral region of the lake (see Supplementary Table 1).

All water samples were collected by a water-column sample device from the middle of the water level in 2 L amber silanized glass bottles with Teflon-faced caps. One litre of each sample was acidified by applying 100% formic acid (due to sorbent type compatibility) to pH 3.5–4.0. Internal standards (Citalopram-d6, Carbamazepine-d10, E2-13C3, and N-ethylloxazepam) were added to samples before filtration; the final concentration was 5 ng/L for each standard and these were used for the quantification of samples. After spiking by internal standards, samples were vacuum filtered through a GF/F 0.7 μm glass microfibre filter (#516-0345, VWR). The Solid Phase Extraction (SPE) of samples was implemented using AutoTrace 280 automated SPE system (Thermo Scientific). SPE extracts were evaporated using an inert nitrogen gas stream. Analytical measurements and detection were performed using an ACQUITY UPC2 Supercritical Fluid Chromatography System (Waters) coupled with a Xevo TQ-S Triple Quadrupole Mass Spectrometer (Waters). Data were recorded by MassLynx software (V4.1 SCN950) and evaluated by TargetLynx XS software. The details of analytical measurements with validation parameters of measured PhACs and data evaluation is published in our previous paper (Maasz et al. 2019).

**Calculation of ERA**

ERA is based on ecotoxicological threshold data from experiments on aquatic organisms (algae, Cladocera [usually *Daphnia* sp.], and/or fish species). Accordingly, E(L)C50 and NOEC values derived from acute and chronic tests, respectively, are taken into consideration. Applying them, the SSD curve and the hazard concentrations (e.g., HC5, which 5% of the species in the SSD exhibit an effect; Supplementary Fig. 2) are also determined by Chemical Aquatic Fate and Effects (CAFE) database and software (Bejarano et al. 2016). Using these data, the PNEC is calculated (Eq. 1) as the ratio of the E(L)C50, NOEC or HC5 data and an Assessment Factor (AF);

\[
PNEC = \frac{E(L)C50 \text{ or NOEC or HC5}}{AF}
\]  

The magnitude of the AF depends on the available toxicological information. The reliability of the results increases if toxicological data for aquatic organisms are available at multiple different trophic levels. Hence, the value of AF is decreased in cases of large and relevant datasets. For example, if toxicity data are only available based on E(L)C50 an AF of 1000 is used, but where NOEC is derived from experiments with a single trophic level (e.g., fish), an AF of 100 is applied and if NOEC for two trophic levels are available (e.g., fish and Cladocera), AF = 50 is used. If NOECs are known for all three trophic levels then AF is equal to 10 (Hamre 2006). In case of using at least five different species (independently on trophic levels) with the same toxicological data, meaning the HC5 value is known, AF = 5 (Amiard and Amiard-Triquet, 2015).
If different toxicity data are available for each trophic level, the lowest concentration limit results will be used to determine PNEC, as ERA is based on the most sensitive elements of the ecosystem, in order to estimate ecological hazard for the worst-case scenario (Thomaidi et al. 2015).

If no experimental toxicological data are available then predicted E(L)C50 values from the US Environmental Protection Agency Ecological Structure Activity Relationships Class Program (ECOSAR database) are usually used (Sanderson et al. 2004) however, the data from this database are highly uncertain, therefore, the applicable AF = 1000 (Zhang et al. 2017).

ERA characterization is possible after measurement of environmental concentrations and determination of the toxicology threshold values of investigated pollutants, because RQ, which is used to categorize harmful effects for the ecosystem, is defined as the ratio of the maximum MEC to the PNEC (Eq. 2);

\[ RQ = \frac{MEC}{PNEC} \]  

In general, RQ < 0.01 denotes a negligible risk, RQ < 0.1 reveals a low risk, 0.1 < RQ < 1 represents a medium risk, and RQ > 1 indicates a high ecological risk to aquatic organisms (Ma et al. 2016; EU Commission 2003).

The following method was used to track risk levels over time. From the six sampling sites (Fig. 1), the highest MEC was selected for each PhAC and investigated month. Their maximum RQ values among six sampled sites were defined as the maxRQ. From the highest maxRQ in each sampled month was determined, termed maxRQperiod; this is independent of the kind of PhAC and its relationship over time can be studied. When the highest maxRQs were calculated for the whole studied period, separately for each PhAC, we generally define this value as MAX RQ values. Based on MAX RQs, the different level of risk (high, medium, low, and negligible) for each PhACs can be determined in the whole investigation period (see Supplementary Table 2).

In the vast majority of aquatic mixture toxicity studies, the toxicity of a mixture is assessed by Concentration Addition (CA) model, neglected the toxic modes of action of the mixture constituents. The CA model implies that the contribution of the individual toxicants to the overall effect can be added in the form of Toxic Units (TU). The CA of a mixture can be described by the following equation (De Zwart and Posthuma 2005) with slight modifications:

\[ TU = \sum_{i=1}^{n} \frac{MEC_i}{E(L)C50_i \text{ or } NOEC_i} \]  

where MEC\textsubscript{i}, is the actual concentrations and E(L)C50\textsubscript{i} or NOEC\textsubscript{i} is the exposure concentrations of a given PhAC that cause the same standard toxicological response for all
compounds. The TU is a dimensionless expression. It has only one threshold; if its value is greater than 1, it implies a potential risk.

Results and discussion

Seasonal changes in PhACs concentration and ERA

New PhACs, theophylline (28.9-59.6 ng/L), barbital (94.8 ng/L) and diclofenac (5.3-419.4 ng/L) (see detailed in Supplementary Table 1) were detected in the lake in addition to the 39 compounds published earlier (Maasz et al. 2019). The collection of the necessary raw predicted and/or experimental toxicological data (E(L)C50, NOEC, and HC5) and the determination of AF and PNEC values of 42 PhACs, summarized in Table 1, were essential to perform ERA. Table 1 contains various PNEC values in case of some PhACs. For example, 6 different PNECs were calculable in range of 0.1-44.0 in the case of E2 from available ecotoxicological data. However, if the data collection is not sufficiently thorough and the selection method among them is not appropriate (e.g., ECOSAR is applied instead of available laboratory data, or acute experimental results are used in place of known chronic outcomes), the ERA will also be wrong even in orders of magnitude. Since the experimental toxicological data and realistic PNEC values were found only in case of 16 PhACs from 42, ERA and seasonal fluctuation of RQs were emphasized to these compounds in this study. Table 2 shows the results of the ERA (based on RQ values) calculated from MEC, and the PNEC data. The highest RQ values in the months investigated (maxRQperiod) were as follows: 9.80 (June 2017; E2), 1.23 (August 2017; E1), 0.43 (November 2017; E1), 0.51 (April 2018; E1), 5.58 (June 2018, diclofenac), 39.50 (August 2018; diclofenac), and 30.60 (October 2018; diclofenac). Therefore, based on these results, we concluded that the values of maxRQperiod varied seasonally. The seasonal fluctuation of maxRQperiod was plotted and displayed in Fig. 2, this is the first study to present such investigation in freshwater lakes. This fluctuation in our study area was caused by changes in the presence and concentration of E1, E2, and diclofenac especially. The risk of these PhACs presented was typically higher during the summer seasons (e.g., caffeine: 1.16, E2: 9.80, and E1: 5.52 in June or August) than in any other months investigated (e.g., caffeine: 0.00 [<LOQ], E2: 0.00 [<LOQ], and E1: 0.43 in November). Similar season-influenced phenomena in detected environmental concentration values of recreational substances (e.g., illicit drugs) have already been observed in Lake Balaton by our research group (Maasz et al. 2019) and the occurrence and concentration of other PhACs (e.g., methamphetamine, amphetamine, ketamine, and ephedrine) have been also reported in the urban rivers of Beijing in China (Zhang et al. 2017). The frequency of occurrence and levels of several PhACs (e.g., carbamazepine, caffeine, citalopram, and diclofenac) have also been found to differ by season in River Ceyhan in Turkey (Guzel et al. 2019) and Xiangjiang River in China (Lin et al. 2018).

Regarding the contamination input aspect of surface water, the environmental concentrations of PhACs vary depending on their chemical stability, biodegradability, physicochemical characteristics, and the efficiency of WWT technology (Bouissou-Schurtz et al. 2014). For example, microbiological
activity is influenced by temperature during WWT, as the efficiency of bacterial removal decreases in winter (Couto et al. 2019). Climate effects (e.g., temperature, ultraviolet exposure, rainfall, wind) can also modify the measured concentration of PhACs at the investigated sites (Zhang et al. 2017). Moreover, change of season affects tourists, thereby the spatial distribution of the population, and, as consumption and excretion of PhACs contribute to the detected contamination, the impact of tourism cannot be neglected. Additionally, the typical health problems and most-consumed PhACs change depending on weather conditions and season. For some PhACs, seasonal consumption patterns were also observed; for example, some antipyretics (e.g., diclofenac, ibuprofen, and naproxen) have higher usage rates during winter than spring, summer or autumn. At the same time, similar to our observations in this study, other PhACs such as carbamazepine showed a similar presence in all seasonal periods (Camacho-Munoz et al. 2014; Couto et al. 2019). Consequently, the season-influenced phenomenon of PhACs is the outcome of a very difficult, complex, and multi-factor process.

As Table 2 indicates, based on our MAX RQ data, 4 PhACs in Lake Balaton were > 1 including diclofenac (39.50), E2 (9.80), E1 (5.52), and caffeine (1.16), indicating high ecological risk for freshwater ecosystems. Another 3 PhACs received a medium (EE2 [0.41], E3 [0.28], citalopram [0.24]) classification and the remaining 9 were negligible. A study collecting the PhACs concentrations in European surface waters and performing ERA have already reported high risk levels in case of all 7 compounds, although the standard method of calculating ERA based on maximal MECs results in overestimation of the actual risk levels. To avoid overestimation, updated RQs can be assessed considering the frequency that MECs exceed PNECs, and using mean MECs instead of maximal MECs (Zhou et al. 2019). Our data were also investigated using this improved method; the updated ERA results showed that risk of PhACs decreases at least one level compared with MAX RQs (data not shown), however, seasonal effects can be better observed considering the maxRQperiod values presented in this paper.

Mixture effect of the examined 16 PhACs was estimated based on their NOEC levels. The characteristic shape of the TU (De Zwart and Posthuma 2005) curve reflects the seasonal variations of mixture effect, as well. Figure 3 shows that the TU and number of guest nights change together depending on time, their maximum values (TU: 22.75, and guest night: ~871,000 in August) are in high tourist seasons while their minimum ones (TU: 0.01, and guest night: ~309,000 in November) are out of season. Although with only a difference of one order of magnitude, but the fluctuation of mixture RQ shows similar seasonal changes in Xiangjiang River (Lin et al. 2018) like TU observing in our study area. Since the data used to calculate the mixture RQs are derived from RQs, they can be categorized as the same risk criteria. However, as already mentioned, TU has only one threshold. If its value greater than 1, it indicates a possible risk.

This is the first ERA based on changes in maxRQperiod values from a specific case study in Lake Balaton, which makes an effort to prove the harmful effect of summer tourist months on a freshwater lake.
Summary

Season-dependent fluctuation of magnitude of risk is apparent (maxRQperiod, Fig. 2.), therefore our hypothesis that the environmental risk increases during the holiday season in the study area, Lake Balaton, is proven. However, it must be noted that only 16 PhACs from the 42 presenting magnitude of the risk because they have available experimental ecotoxicological data (NOEC) applied to ERA. According to our results when considering all MAX RQs presented, the PhACs with at least medium risk level were caffeine, citalopram, diclofenac, E1, E2, E3, and EE2 in the study area during the period investigated. More attention should be paid to these 7 PhACs in the future in order to diagnose and predict their effects on aquatic ecosystems. The TU curve (Fig. 3.) reflects the seasonal variations of mixture effect which correlate well with the change of maxRQperiods and the number of guest nights.

Conclusions

The fluctuation of summed MEC, maxRQperiod, and TU suggested the possibility of harmful effects on aquatic ecosystems in the summer tourist season. Caffeine, citalopram, diclofenac, E1, E2, E3, and EE2 presented at least a medium risk at least once during the whole period of investigation in Lake Balaton, the largest shallow lake in Central Europe, based on MAX RQ results. There is a real need for ongoing water quality monitoring and repeated toxicological testing for PhACs to ensure the real risk levels are understood. Besides, during our work we found several discrepancy in raw ecotoxicological data, therefore, we propose to develop a unified PNEC database, including data regarding habitats, endpoints, and compounds, ensuring reliable and comparable results for ERA.

Funding

This work was supported by the National Brain Project (No. 2017-1.2.1-NKP-2017-00002), a PD-OTKA Grant (No. 124161), and the Bolyai Foundation (No. BO/00952/16/8).

Figure legends

Fig. 1 - Hydrogeography of Lake Balaton. The positions marked from 1 to 6 belong to the near-coastal area of the lake. The sampling points (by coordinates) are as follows: 1 - Szigliget (46.78541, 17.4349), 2 - Révfülöp (46.82411, 17.60672), 3 - Balatonlelle (46.79708, 17.72528), 4 - Tihany-Sajkod (46.90339, 17.85037), 5 - Zamárdi (46.88525, 17.93139), and 6 - Siófok (46.91102, 18.04604)

Fig. 2 - Seasonal fluctuation of maxRQperiods in Lake Balaton in the investigated months. (striped – summer seasons; dashed vertical – autumn seasons; gridded – winter season; waved – spring season) E1 – estrone; E2- estradiol

Fig. 3 - Seasonal fluctuation of TU and number of guest nights in Lake Balaton in the investigated months.

Table 1 - Raw toxicological data for the 42 investigated PhACs. Ecotoxicological data are collected from ECOSAR (Sanderson et al., 2004), and/or CAFE database and/or several papers (see references), with their AF and calculated PNECs in ng/L (n.d. = no data)

Table 2 - MEC data (in ng/L), calculated maxRQ, maxRQperiod, and MAX RQ values of PhACs, as well as risk levels of Lake Balaton in the seven investigated periods (LOQ = limit of quantitation)
References

Amiard JC and Amiard-Triquet C (2015) Conventional Risk Assessment of Environmental Contaminants. In: Aquatic Ecotoxicology Elsevier Inc 25-49 doi: 10.1016/B978-0-12-800949-9.00002-4

Andreozzi R, Marotta R, Pinto G et al. (2002) Carbamazepine in water: persistence in the environment, ozonation treatment and preliminary assessment on algal toxicity. Water Res 36:2869-2877 doi: 10.1016/s0043-1354(01)00500-0

Bejarano AC, Farr JK, Jenne P et al. (2016) The chemical aquatic fate and effects database (CAFE), a tool that supports assessments of chemical spills in aquatic environments. Environ Toxicol Chem 35:1576-1586 doi:10.1002/etc.3289

Bouissou-Schurtz C, Houeto P, Guerbet M et al. (2014) Ecological risk assessment of the presence of pharmaceutical residues in a French national water survey. Regul Toxicol Pharmacol 69:296-303 doi:10.1016/j.yrtph.2014.04.006

Camacho-Munoz D, Martin J, Santos JL et al. (2014) Concentration evolution of pharmaceutically active compounds in raw urban and industrial wastewater. Chemosphere 111:70-79 doi:10.1016/j.chemosphere.2014.03.043

Carlsson C, Johansson AK, Alvan G et al. (2006) Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients. Sci Total Environ 364:67-87 doi:10.1016/j.scitotenv.2005.06.035

Clubbs RL, Brooks BW (2007) Daphnia magna responses to a vertebrate estrogen receptor agonist and an antagonist: A multigenerational study. Ecotoxicol Environ Saf 67:385–398 doi:10.1016/j.ecoenv.2007.01.009

Couto CF, Lange LC, Amaral MCS (2019) Occurrence, fate and removal of pharmaceutically active compounds (PhACs) in water and wastewater treatment plants - A review. J Water Process Eng 32:100927 doi:10.1016/j.jwpe.2019.100927

Dammann AA, Shappell NW, Bartell SE et al. (2011) Comparing biological effects and potencies of estriol and 17β-estradiol in mature fathead minnows, Pimephales promelas. Aquat Toxicol 105:559–568 doi:10.1016/j.aquatox.2011.08.011

Daughton CG, Ternes TA (1999) Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ Health Perspect 107 Suppl 6:907-938 doi:10.1289/ehp.99107s6907

Deo RP (2014) Pharmaceuticals in the surface water of the USA: A Review. Curr Envir Health Rpt 1:113-122 doi:10.1007/s40572-014-0015-y

De Zwart D, Posthuma L (2005) Complex mixture toxicity for single and multiple species: proposed methodologies. Environ Toxicol Chem 24:2665-2676 doi:10.1897/04-639r.1

Diaz-Cruz MS, de Alda MJL, Barcelo D (2003) Environmental behavior and analysis of veterinary and human drugs in soils, sediments and sludge. Trac-Trend Anal Chem 22:340-351 doi:10.1016/S0165-9936(03)00603-4

Dobor J, Varga M, Zaray G (2012) Biofilm controlled sorption of selected acidic drugs on river sediments characterized by different organic carbon content. Chemosphere 87:105-110 doi:10.1016/j.chemosphere.2011.11.067
Dzialowski EM, Turner PK, Brooks BW (2006) Physiological and reproductive effects of beta adrenergic receptor antagonists in *Daphnia magna*. Arch Environ Contam Toxicol 50:503-510 doi:10.1007/s00244-005-0121-9

EU Commission JRC, Loos, R., Marinov, D., Sanseverino, I., Napierska, D., Lettieri, T., (2018) Review of the 1st Watch List Under the Water Framework Directive and Commission Regulation (EC) No 1488/94 on risk assessment for existing substances - Part II (EUR 20418 EN) https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/technical-guidance-document-risk-assessment-part-1-part-2

Ferrari B, Mons R, Vollat B et al. (2004) Environmental risk assessment of six human pharmaceuticals: are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment? Environ Toxicol Chem 23:1344-1354 doi:10.1897/03-246

Ginebreda A, Munoz I, de Alda ML et al. (2010) Environmental risk assessment of pharmaceuticals in rivers: relationships between hazard indexes and aquatic macroinvertebrate diversity indexes in the Llobregat River (NE Spain). Environ Int 36:153-162 doi:10.1016/j.envint.2009.10.003

Guzel EY, Cevik F, Daglioglu N (2019) Determination of pharmaceutical active compounds in Ceyhan River, Turkey: Seasonal, spatial variations and environmental risk assessment. Hum Ecol Risk Assess 25:1980-1995 doi:10.1080/10807039.2018.1479631

Hamre HT (2006) Initial assessment of eleven pharmaceuticals using the EMEA guideline in Norway. Oslo. ISBN 82-7655-295-1

Helwig K, Hunter C, McNaughtan M et al. (2016) Ranking prescribed pharmaceuticals in terms of environmental risk: Inclusion of hospital data and the importance of regular review. Environ Toxicol Chem 35:1043-1050 doi:10.1002/etc.3302

Hernando MD, Mezcua M, Fernandez-Alba AR et al. (2006) Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. Talanta 69:334-342 doi:10.1016/j.talanta.2005.09.037

Heys KA, Shore RF, Pereira MG et al. (2016) Risk assessment of environmental mixture effects. RSC Adv 6:47844-47858 doi:10.1039/c6ra05406d

Istvanovics V, Clement A, Somlyody L et al. (2007) Updating water quality targets for shallow Lake Balaton (Hungary), recovering from eutrophication. Hydrobiol 581:305-318

Jiahua G (2015) Impact of pharmaceuticals on algal species. PhD dissertation. The University of York, UK. http://etheses.whiterose.ac.uk/id/eprint/12390

Julius ML, Stepanek J, Tedrow O et al. (2007) Estrogen-receptor independent effects of two ubiquitous environmental estrogens on Melosira varians Agardh, a common component of the aquatic primary production community. Aquat Toxicol 85:19-27 doi:10.1016/j.aquatox.2007.07.010
Kashian DR, Dodson SI (2004) Effects of vertebrate hormones on development and sex determination in *Daphnia Magna*. Environ Toxicol Chem 23:1282-1288 doi:10.1897/03-372

Katircioğlu ST (2014) International tourism, energy consumption, and environmental pollution: The case of Turkey. Renew Sust Energ Rev 36:180-187 doi:10.1016/j.rser.2014.04.058

Komori K, Suzuki Y, Minamiyama M et al. (2013) Occurrence of selected pharmaceuticals in river water in Japan and assessment of their environmental risk. Environ Monit Assess 185:4529-4536 doi:10.1007/s10661-012-2886-4

Kristensen T, Baatrup E, Bayley M (2005) 17α-ethinylestradiol reduces the competitive reproductive fitness of the male guppy (*Poecilia reticulata*). Biol Reprod 72:150–156 doi:10.1095/biolreprod.104.033001

Kummerer K (2004) Resistance in the environment. J Antimicrob Chemother 54:311-320 doi:10.1093/jac/dkh325

La Farre M, Perez S, Kantiani L et al. (2008) Fate and toxicity of emerging pollutants, their metabolites and transformation products in the aquatic environment. Trac-Trend Anal Chem 27:991-1007 doi:10.1016/j.trac.2008.09.010

Lahnsteiner F, Berger B, Kletzl M et al. (2006) Effect of 17β-estradiol on gamete quality and maturation in two salmonid species. Aquat Toxicol 79:124-131 doi:10.1016/j.aquatox.2006.05.011

Lange R, Dietrich D (2002) Environmental risk assessment of pharmaceutical drug substances-conceptual considerations. Toxicol Lett 131:97-104 doi:10.1016/s0378-4274(02)00071-1

Lei B, Kang J, Yu Y et al. (2014) Long-term exposure investigating the estrogenic potency of estriol in Japanese medaka (*Oryzias latipes*). Comp Biochem Phys Part C: 160:86–92 doi:10.1016/j.cbpc.2013.11.001

Lin H, Chen L, Li H et al. (2018) Pharmaceutically active compounds in the Xiangjiang River, China: Distribution pattern, source apportionment, and risk assessment. Sci Total Environ 636:975-984 doi:10.1016/j.scitotenv.2018.04.267

Liu G, Li Z, Liu J (2013) Effects of selected pharmaceuticals on growth, reproduction and feeding of *Daphnia Magna*. In:Fresenius Environmental Bulletin 22:2583-258 ISSN:1018-4619

Lurling M, Sargent E, Roessink I (2006) Life-history consequences for *Daphnia pulex* exposed to pharmaceutical carbamazepine. Environ Toxicol 21:172–180 doi:10.1002/tox.20171

Ma R, Wang B, Lu S et al. (2016) Characterization of pharmaceutically active compounds in Dongting Lake, China: Occurrence, chiral profiling and environmental risk. Sci Total Environ 557-558:268-275 doi:10.1016/j.scitotenv.2016.03.053

Maasz G, Mayer M, Zrinyi Z et al. (2019) Spatiotemporal variations of pharmacologically active compounds in surface waters of a summer holiday destination. Sci Total Environ 677:545-555 doi:10.1016/j.scitotenv.2019.04.286

Madureira TV, Rocha MJ, Cruzeiro C et al. (2011) The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal): Assessing impacts on gonadal maturation with a histopathological and stereological study of zebrafish ovary and testis after sub-acute exposures. Aquat Toxicol 105:292–299 doi:10.1016/j.aquatox.2011.06.017

Marcial HS, Hagiwara A, Snell TW (2003) Estrogenic compounds affect development of harpacticoid copepod *Tigriopus japonicus*. Environ Toxicol Chem 22:3025-3030 doi:10.1897/02-622

Mendoza A, Rodriguez-Gil JL, Gonzalez-Alonso S et al. (2014) Drugs of abuse and benzodiazepines in the Madrid Region (Central Spain): seasonal variation in river...
waters, occurrence in tap water and potential environmental and human risk.

Mennigen JA, Sassine J, Trudeau VL et al. (2010) Waterborne fluoxetine disrupts feeding and energy metabolism in the goldfish Carassius auratus. Aquat Toxicol 100:128–137 doi:10.1016/j.aquatox.2010.07.022

Mihalic T (2000) Environmental management of a tourist destination: A factor of tourism competitiveness. Tour Manag 21:65-78 doi:10.1016/S0261-5177(99)00096-5

Nakada N, Hanamoto S, Jurgens MD et al. (2017) Assessing the population equivalent and performance of wastewater treatment through the ratios of pharmaceuticals and personal care products present in a river basin: Application to the River Thames basin, UK. Sci Total Environ 575:1100-1108 doi:10.1016/j.scitotenv.2016.09.180

Nallani GC, Edziyie RE, Paulos PM et al. (2016) Bioconcentration of two basic pharmaceuticals, verapamil and clozapine, in fish. Environ Toxicol Chem 35:593–603. doi:10.1002/etc.3244

Oggier DM, Weisbrod CJ, Stoller AM et al. (2010) Effects of diazepam on gene expression and link to physiological effects in different life stages in zebrafish Danio rerio. Environ Sci Technol 44:7685–7691 doi:10.1021/es100980r

Olsen KH, Ask K, Olsen H et al. (2014) Effects of the SSRI citalopram on behaviours connected to stress and reproduction in Endler guppy, Poecilia wingei. Aquat Toxicol 148:113–121 doi:10.1016/j.aquatox.2013.12.032

Posthuma L, Suter GW II, Traas TP eds. (2002) Species sensitivity distribution in ecotoxicology. Lewis, Boca Raton, FL, USA

Routledge EJ, Sheahan D, Desbrow C et al. (1998) Identification of estrogenic chemicals in STW effluent. 2. In vivo responses in trout and roach. Environ Sci Technol 32:1559-1565 doi:10.1021/Es970796a

Sanderson H, Johnson DJ, Reitsma T et al. (2004) Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul Toxicol Pharmacol 39:158–183 doi:10.1016/j.yrtph.2003.12.006

Schwaiger J, Ferling H, Mallow U et al. (2004) Toxic effects of the non-steroidal anti-inflammatory drug diclofenac. Aquat Toxicol 68:141–150 doi:10.1016/j.aquatox.2004.03.014

Thomaidi VS, Stasinakis AS, Borova VL et al. (2015) Is there a risk for the aquatic environment due to the existence of emerging organic contaminants in treated domestic wastewater? Greece as a case-study. J Hazard Mater 283:740-747 doi:10.1016/j.jhazmat.2014.10.023

Vestel J, Caldwell DJ, Constantine L et al. (2016) Use of acute and chronic ecotoxicity data in environmental risk assessment of pharmaceuticals. Environ Toxicol Chem 35:1201-1212 doi:10.1002/etc.3260

Webb SF (2001) A data based perspective on the environmental risk assessment of human pharmaceuticals II — Aquatic risk characterisation. In: Kummerer K (ed) Pharmaceuticals in the environment. Springer, Berlin, Heidelberg, 203-219. doi:10.1007/978-3-662-04634-0_16

Wu F, Fang Y, Li Y et al. (2014) Predicted no-effect concentration and risk assessment for 17-[beta]-estradiol in waters of China. Rev Environ Contam Toxicol 228:31-56 doi:10.1007/978-3-319-01619-1_2
Zhang W, Zhang M, Lin K et al. (2012) Eco-toxicological effect of carbamazepine on *Scenedesmus obliquus* and *Chlorella pyrenoidosa*. Environ Toxicol Pharmacol 33:344–352 doi:10.1016/j.etap.2011.12.024

Zhang Y, Zhang T, Guo C et al. (2017) Drugs of abuse and their metabolites in the urban rivers of Beijing, China: Occurrence, distribution, and potential environmental risk. Sci Total Environ 579:305-313 doi:10.1016/j.scitotenv.2016.11.101

Zhou S, Di Paolo C, Wu X et al. (2019) Optimization of screening-level risk assessment and priority selection of emerging pollutants – The case of pharmaceuticals in European surface waters. Environ Int 128:1-10 doi:10.1016/j.envint.2019.04.034
Figure 2
Figure 3

- TU
- Number of guest nights

Seasons:
- Summer
- Autumn
- Winter
- Spring
- Summer
- Autumn
| PhACs          | Ecotoxicological data                                                                 | Ref.            |
|---------------|-------------------------------------------------------------------------------------|-----------------|
|               | Based on acute test results                                                         |                 |
|               | E(L)C₅₀(algae) | E(L)C₅₀(Cladocera) | E(L)C₅₀(fish) | NOEC(algae) | NOEC(Cladocera) | NOEC(fish) | Based on SSD | AF       | PNEC     |
|               | (mg/L)        | (mg/L)              | (mg/L)       | (mg/L)      | (mg/L)         | (mg/L)     |             | (mg/L)   | (mg/L)   |
| alprazolam    | 6.28E+05      | 5.08E+05            | 5.41E+06     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 5.08E+02 | Sanderson et al. 2004 |
| atropine      | 2.66E+06      | 6.64E+06            | 2.00E+07     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 2.66E+03 | Sanderson et al. 2004 |
| barbital      | n.d.          | n.d.                | 1.16E+09     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 1.16E+06 | Sanderson et al. 2004 |
| benzoylecgonine | 1.20E+10     | 6.81E+09            | 3.35E+10     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 6.81E+06 | Mendoza et al. 2014 |
| bisoprolol    | 3.15E+06      | 8.20E+06            | 1.13E+08     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 3.15E+03 | Sanderson et al. 2004 |
| bupropion     | 3.30E+06      | 9.50E+05            | 3.30E+07     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 9.50E+02 | Vestel et al. 2016 |
| buspirone     | 2.60E+06      | 5.16E+06            | 6.70E+07     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 2.60E+03 | Sanderson et al. 2004 |
| caffeine      | 8.56E+06      | 4.70E+07            | 8.05E+08     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 6.85E+03 | Sanderson et al. 2004 |
| carbamazepine | 8.15E+06      | 6.36E+06            | 1.40E+07     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 6.36E+03 | Sanderson et al. 2004 |
| citalopram    | 7.29E+05      | 6.35E+05            | 6.88E+06     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 6.35E+02 | Sanderson et al. 2004 |
| clozapine     | 1.47E+06      | 2.15E+06            | 2.60E+07     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 1.47E+03 | Sanderson et al. 2004 |
| cocaine       | 2.28E+06      | 4.91E+06            | 1.30E+07     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 2.85E+02 | Nalliani, 2010 |
| diazepam      | 1.42E+06      | 2.26E+06            | 2.80E+07     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 1.42E+03 | Sanderson et al. 2004 |
| diclofenac    | 7.71E+06      | 4.24E+06            | 4.94E+06     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 4.24E+03 | Sanderson et al. 2004 |
| E1            | 1.66E+06      | 5.60E+05            | 7.40E+04     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 7.40E+01 | Sanderson et al. 2004 |
| E2            | 8.00E+05      | 2.77E+05            | 4.40E+04     | n.d.       | n.d.           | n.d.       | 1.00E+03    | 4.40E+01 | Sanderson et al. 2004 |
|               |                |                     |              | n.d.       | n.d.           | n.d.       | 1.00E+03    | 4.00E-01 | EU JRC, 2018     |
|               |                |                     |              | n.d.       | n.d.           | n.d.       | 3.60E+00    | 3.60E+00 | EU JRC, 2018     |
|               |                |                     |              | n.d.       | n.d.           | n.d.       | 1.00E+02    | 1.00E+02 | Dammant et al. 2011 |
|               |                |                     |              | n.d.       | n.d.           | n.d.       | 1.00E+02    | 1.00E+02 | Dammant et al. 2011 |
|               |                |                     |              | n.d.       | n.d.           | n.d.       | 1.00E+01    | 1.00E+01 | Julius et al. 2007 |
|               |                |                     |              | n.d.       | n.d.           | n.d.       | 1.00E+01    | 1.00E+01 | Marcial et al. 2003 |
|               |                |                     |              | n.d.       | n.d.           | n.d.       | 1.00E+01    | 1.00E+01 | Routledge et al. 1998; Lahnsteiner et al. 2006 |
|               |                |                     |              | n.d.       | n.d.           | n.d.       | 7.30E-01    | 7.30E-01 | Wu et al. 2014  |
| n.d. | n.d. | n.d. | n.d. | n.d. | 1.00E+01 | 5.00E+00 | 2.00E+00 | CAFE  |
|------|------|------|------|------|----------|----------|----------|-------|
| E3   | 4.39E+06 | 1.45E+06 | 1.50E+04 | n.d. | n.d. | n.d. | 1.00E+03 | 1.50E+01 | Sanderson et al. 2004 |
| n.d. | n.d. | n.d. | n.d. | n.d. | 4.65E+01 | n.d. | 1.00E+02 | 4.65E-01 | Lei et al. 2014 |
| EE2  | 6.77E+05 | 2.34E+05 | 4.00E+04 | n.d. | n.d. | n.d. | 1.00E+03 | 4.00E+01 | Sanderson et al. 2004 |
| n.d. | n.d. | n.d. | n.d. | n.d. | 4.40E+01 | n.d. | 1.00E+02 | 4.40E-01 | Kristensen et al. 2005 |
| fluoxetine | 3.45E+05 | 1.78E+05 | 1.72E+06 | n.d. | n.d. | n.d. | 1.00E+03 | 1.78E+02 | Sanderson et al. 2004 |
| n.d. | n.d. | n.d. | n.d. | 7.20E+04 | n.d. | n.d. | 5.00E+01 | 1.08E+03 | Menning et al. 2010 |
| ketamin | 8.61E+05 | 1.07E+06 | 1.30E+07 | n.d. | n.d. | n.d. | 1.00E+03 | 8.61E+02 | Sanderson et al. 2004 |
| lamotrigine | n.d. | n.d. | n.d. | n.d. | 1.50E+10 | n.d. | 1.00E+02 | 1.50E+08 | Do 2014 |
| levonorgestrel | 2.28E+06 | 1.31E+06 | 5.56E+05 | n.d. | n.d. | n.d. | 1.00E+03 | 5.56E+02 | Sanderson et al. 2004 |
| lidocaine | 2.61E+06 | 7.52E+06 | 1.07E+08 | n.d. | n.d. | n.d. | 1.00E+03 | 2.61E+03 | Sanderson et al. 2004 |
| losartan | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | 1.90E+03 | Helwig et al. 2016 |
| MDMA | 2.30E+06 | 2.16E+05 | 2.42E+07 | n.d. | n.d. | n.d. | 1.00E+03 | 2.16E+02 | Mendoza et al. 2014 |
| methadone | 4.12E+07 | 3.81E+07 | 1.10E+08 | n.d. | n.d. | n.d. | 1.00E+03 | 3.81E+04 | Sanderson et al. 2004 |
| metoprolol | n.d. | n.d. | n.d. | n.d. | 6.15E+06 | n.d. | 1.00E+02 | 6.15E+04 | Dziadowski et al. 2006 |
| midazolam | 4.65E+05 | 2.89E+05 | 2.90E+06 | n.d. | n.d. | n.d. | 1.00E+03 | 2.89E+02 | Sanderson et al. 2004 |
| mirtazapine | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | 3.20E+04 | Helwig et al. 2016 |
| naproxen | 2.30E+07 | 1.51E+07 | 2.43E+07 | n.d. | n.d. | n.d. | 1.00E+03 | 1.51E+04 | Sanderson et al. 2004 |
| nordiazepam | 1.19E+06 | 1.71E+06 | 2.10E+07 | n.d. | n.d. | n.d. | 1.00E+03 | 1.19E+03 | Sanderson et al. 2004 |
| olanzapine | 1.41E+08 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | 1.41E+05 | Jishna 2015 |
| perindopril | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | 9.90E+05 | Webb 2001 |
| progesterone | 3.30E+06 | 1.00E+06 | 7.33E+05 | n.d. | n.d. | n.d. | 1.00E+03 | 7.33E+02 | Sanderson et al. 2004 |
| quetiapine | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | 1.00E+03 | 1.00E+04 | AstraZeneca |
| testosterone | 2.90E+06 | 1.70E+06 | 1.43E+06 | n.d. | n.d. | n.d. | 1.00E+03 | 1.43E+03 | Sanderson et al. 2004 |
| tetraacycline | 7.45E+05 | 1.36E+06 | 2.20E+06 | n.d. | n.d. | n.d. | 1.00E+03 | 7.45E+02 | Sanderson et al. 2004 |
| theophylline | 9.70E+06 | 1.00E+06 | 1.68E+09 | n.d. | n.d. | n.d. | 1.00E+03 | 1.00E+03 | Sanderson et al. 2004 |
| tiapride | 8.72E+06 | 4.80E+07 | 7.89E+08 | n.d. | n.d. | n.d. | 1.00E+03 | 8.72E+03 | Sanderson et al. 2004 |
| tramadol | 1.04E+06 | 3.20E+04 | 7.72E+06 | n.d. | n.d. | n.d. | 1.00E+03 | 3.20E+01 | Sanderson et al. 2004 |
| verapamil | n.d. | n.d. | 3.60E+07 | n.d. | n.d. | n.d. | 1.00E+03 | 3.60E+04 | Sanderson et al. 2004 |
| zolpidem | 6.35E+05 | 5.19E+05 | 5.54E+06 | n.d. | n.d. | n.d. | 1.00E+03 | 5.19E+02 | Sanderson et al. 2004 |
| PhACs       | June 2017 | August 2017 | November 2017 | April 2018 | June 2018 | August 2018 | October 2018 | June 2017 - October 2018 |
|-------------|-----------|-------------|---------------|------------|-----------|-------------|---------------|-------------------------|
|             | MEC [ng/L] | maxRQ       | MEC [ng/L]    | maxRQ      | MEC [ng/L]| maxRQ       | MEC [ng/L]    | maxRQ               | MEC [ng/L] | maxRQ       | MEC [ng/L] | maxRQ       | MEC [ng/L] | maxRQ       | Level of risk |
| diclofenac  | <LOQ      | <LOQ        | <LOQ          | <LOQ       | -         | -           | -             | -                     | -          | -           | -          | -           | -          | -           | high          |
| E2          | 1.96E+01  | 9.80E+00    | 2.00E-01      | 1.00E-01   | <LOQ      | -           | 1.95E-01     | 9.75E-02             | 3.00E+00   | 1.50E+00   | <LOQ       | -           | 6.50E-02   | 3.25E-02    | 9.80E+00      |
| E1          | 5.52E+00  | 5.52E+00    | 1.23E+00      | 1.23E+00   | <LOQ      | -           | 5.10E-01     | 5.10E-01             | <LOQ       | -           | 1.81E+00  | 1.81E+00   | 4.25E-01   | 4.25E-01    | 5.52E+00      |
| caffeine    | <LOQ      | 8.99E+01    | 3.88E-02      | <LOQ       | -         | <LOQ        | 1.39E+03     | 6.00E-01             | 2.68E+03   | 1.16E+00   | 2.42E+03  | 1.04E+00   | 1.16E+00   | 1.16E+00    | high          |
| EE2         | <LOQ      | <LOQ        | <LOQ          | 1.80E-01   | 4.09E-01  | <LOQ        | <LOQ         | -                     | <LOQ       | -           | <LOQ       | -           | -          | 4.09E-01    | medium        |
| E3          | 1.00E-01  | 2.15E-01    | 1.30E-01      | 2.80E-01   | <LOQ      | -           | <LOQ         | -                     | <LOQ       | -           | <LOQ       | -           | 2.80E-01   | medium       | medium        |
| citalopram  | 1.30E-01  | 1.30E-02    | 2.00E-01      | 2.00E-02   | <LOQ      | -           | 2.44E+00     | 2.44E-01             | <LOQ       | -           | <LOQ       | -           | <LOQ       | <LOQ         | medium        |
| carbamazepine| 6.88E+01  | 6.88E+03    | 4.63E+01      | 4.63E-03   | 1.59E+01  | 1.59E-03    | 7.75E+01     | 7.75E-03             | 1.45E+01   | 1.45E-03    | 1.66E+01 | 2.41E-03   | 2.41E-03   | 7.75E-03    | negligible   |
| clozapine   | 5.40E-01  | 1.89E-03    | 5.50E-01      | 1.93E-03   | <LOQ      | -           | <LOQ         | -                     | <LOQ       | -           | <LOQ       | -           | 2.04E-05   | 8.26E-05    | negligible   |
| fluoxetine  | 1.68E+00  | 1.56E-03    | <LOQ          | -          | <LOQ      | <LOQ        | <LOQ         | -                     | <LOQ       | -           | <LOQ       | -           | <LOQ       | <LOQ         | negligible   |
| progesterone| 9.60E-01  | 9.60E-04    | 1.31E+00      | 1.31E-03   | <LOQ      | <LOQ        | <LOQ         | -                     | <LOQ       | -           | <LOQ       | -           | 1.31E-03   | negligible   |
| testosterone| <LOQ      | <LOQ        | <LOQ          | <LOQ       | -         | -           | -             | -                     | -          | -           | -          | -           | -          | -           | negligible   |
| diazepam    | <LOQ      | <LOQ        | <LOQ          | <LOQ       | 2.50E-01  | 9.62E-05    | <LOQ         | -                     | <LOQ       | -           | <LOQ       | -           | 9.62E-05   | negligible   |
| metoprolol  | <LOQ      | 5.08E+00    | 8.26E-05      | <LOQ       | -         | <LOQ        | <LOQ         | -                     | <LOQ       | -           | <LOQ       | -           | <LOQ       | <LOQ         | negligible   |
| quetiapine  | 1.20E-01  | 1.20E-05    | 1.10E-01      | 1.10E-05   | <LOQ      | -           | <LOQ         | -                     | <LOQ       | -           | <LOQ       | -           | 1.20E-05   | negligible   |
| lamotrigine | 8.57E+00  | 5.71E-08    | 1.62E+02      | 1.08E-06   | 2.21E+01  | 1.47E-07    | 3.34E+01     | 2.23E-07             | <LOQ       | -           | <LOQ       | -           | 5.54E-01  | 3.69E-07    | negligible   |

| maxRQperiod | 9.80E+00 | 1.23E+00 | 4.30E-01 | 5.10E-01 | 5.58E+00 | 3.95E+01 | 3.06E+01 | 0.91E+01

**Table 2**
Supplementary information

Environmental risk assessment of pharmaceuticals at a seasonal holiday destination in the largest freshwater shallow lake in Central Europe

Eva Molnar, Gabor Maasz*, Zsolt Pirger

Adaptive Neuroethology Research Group, Department of Experimental Zoology, Balaton Limnological Institute, MTA Centre for Ecological Research, 8237 Tihany, Hungary

*Correspondence to Dr Gabor Maasz, Adaptive Neuroethology Research Group, Department of Experimental Zoology, Balaton Limnological Institute, MTA Centre for Ecological Research, 8237 Tihany, Hungary

E-mail: maasz.gabor@okologia.mta.hu
| PhACs' groups | June 2017 | August 2017 | November 2017 | April 2018 | June 2018 | August 2018 | October 2018 |
|---------------|-----------|-------------|---------------|------------|-----------|-------------|--------------|
| PhACs' name   | LOQ       |             |               |            |           |             |              |
|               | Site 1    | Site 2      | Site 3        | Site 4     | Site 5    | Site 6      | Site 1       |
| benzodiazepines |          |             |               |            |           |             |              |
| carbamazepine | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| lamotrigine   | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| fluoxetine    | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| mirtazapine   | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| olanzapine    | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| quetiapine    | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| tiagride      | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| anxiolytics   |           |             |               |            |           |             |              |
| alprazolam    | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| buspirone     | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| diazepam      | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| midazolam     | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| nordiazepam   | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| sulpiride     | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| buspironol    | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |
| losartan      | 0,1       | 0,1         | 0,1           | 0,1        | 0,1       | 0,1         | 0,1          |

| MIN | MAX | SUM | [%] |
|-----|-----|-----|-----|
| 0.1 | 0.1 | 0.1 | 0.1 |
| 0.1 | 0.1 | 0.1 | 0.1 |
| 0.1 | 0.1 | 0.1 | 0.1 |
| 0.1 | 0.1 | 0.1 | 0.1 |
| 0.1 | 0.1 | 0.1 | 0.1 |
| 0.1 | 0.1 | 0.1 | 0.1 |
| 0.1 | 0.1 | 0.1 | 0.1 |
| 0.1 | 0.1 | 0.1 | 0.1 |

22
| NSAIDs         | 0.1 | 0.05 | 0.02 | 0.01 | 0.005 | 0.001 | 0.0005 | 0.0001 |
|---------------|-----|------|------|------|-------|-------|--------|--------|
| metoprolol    |     |      |      |      |       |       |        |        |
| perindopril   |     |      |      |      |       |       |        |        |
| verapamil     |     |      |      |      |       |       |        |        |
| ketamin       |     |      |      |      |       |       |        |        |
| bE2           | 5.3 | 1.0  |      |      |       |       |        |        |
| E1            |     |      |      |      |       |       |        |        |
| E3            |     |      |      |      |       |       |        |        |
| EE2           |     |      |      |      |       |       |        |        |
| Levonorgestrel |     |      |      |      |       |       |        |        |
| Progesterone   |     |      |      |      |       |       |        |        |
| Testosterone   |     |      |      |      |       |       |        |        |
| Lidocaine     | 0.1 | 0.4  | 0.1  | 0.05 | 0.02  | 0.01  | 0.005  | 0.001  |
| Tetracaine    | 0.3 | 0.1  | 0.05 | 0.02 | 0.01  | 0.005 | 0.001  | 0.0005 |
|diclofenac     | 0.5 | 0.1  | 0.05 | 0.02 | 0.01  | 0.005 | 0.001  | 0.0005 |
| Naproxen      | 0.5 | 0.2  | 0.1  | 0.05 | 0.02  | 0.01  | 0.005  | 0.001  |
| Methadone     | 1.5 | 0.5  | 0.2  | 0.1  | 0.05  | 0.02  | 0.01   | 0.005  |
| Tramadol      | 2.5 | 0.8  | 0.3  | 0.1  | 0.05  | 0.02  | 0.01   | 0.005  |
| Ketamin       | 2.3 | 0.9  | 0.3  | 0.1  | 0.05  | 0.02  | 0.01   | 0.005  |
| Atropine      | 0.3 | 0.1  | 0.05 | 0.02 | 0.01  | 0.005 | 0.001  | 0.0005 |
| Caffeine      | 0.1 | 0.05 | 0.02 | 0.01 | 0.005 | 0.001 | 0.0005 | 0.0001 |
| Theophyllin   | 0.1 | 0.05 | 0.02 | 0.01 | 0.005 | 0.001 | 0.0005 | 0.0001 |
| Benzoyl-      |     |      |      |      |       |       |        |        |
| ergonine      |     |      |      |      |       |       |        |        |

23
Supplementary Table 1 - Concentration levels of 42 detected PbCAs in 6 sites of Lake Balaton in 7 investigated periods with their limit of quantification (LOQ), minimum (MIN), maximum (MAX) and frequency of occurrence (FO) data, - represents <LOQ
Supplementary Fig. 1 - Seasonal fluctuation of summed MEC (sumMEC) and number of guest nights in Lake Balaton in the investigated months
| PhACs            | June 2017 | August 2017 | November 2017 | April 2018 | June 2018 | August 2018 | October 2018 | June 2017 - October 2018 |
|------------------|-----------|-------------|---------------|------------|-----------|-------------|---------------|--------------------------|
|                  | MEC [ng/L] | maxRQ       | MEC [ng/L]    | maxRQ      | MEC [ng/L]| maxRQ       | MEC [ng/L]    | maxRQ                   |
| E2               | 1.96E+01  | 2.00E-03    | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | <LOQ                    |
|                  | 4.45E-01  | 4.55E-03    | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | <LOQ                    |
|                  | 4.90E+01  | 5.00E-01    | 1.95E-01      | 3.00E+00   | 6.50E-02 | 1.48E-03    | 4.45E-01      | medium                  |
| caffeine         | <LOQ      | 8.99E+03    | 1.31E-02      | 1.39E+03   | 2.03E-01 | 2.68E+03    | 2.24E+03      | negligible               |
|                  | <LOQ      | 3.88E-02    | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | <LOQ                    |
|                  | 9.19E+00  | 1.54E+00    | 4.81E-02      | 9.44E+00   | 9.90E-01 | 7.94E-01    | 2.48E-02      | medium                  |
|                  | 4.90E-01  | 6.10E+00    | 1.91E-01      | 9.02E+00   | 9.90E-01 | 7.94E-01    | 2.48E-02      | low                     |
| tramadol         | <LOQ      | <LOQ        | <LOQ          | 4.19E+00   | 8.38E+00 | 3.24E+02    | 6.80E+00      | high                    |
|                  | <LOQ      | <LOQ        | <LOQ          | 5.91E+01   | 9.89E-02 | 7.65E-02    | 9.80E-02      | high                    |
| diclofenac       | <LOQ      | <LOQ        | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | medium                  |
|                  | <LOQ      | <LOQ        | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | low                     |
|                  | 7.46E-02  | 1.66E-02    | 4.30E-01      | 1.18E-01   | 4.25E-01 | 5.74E-03    | 7.48E-02      | high                    |
|                  | 1.53E+00  | 1.23E+00    | 5.81E-03      | 1.42E-01   | 1.81E+00 | 1.18E-01    | 1.53E+00      | low                     |
|                  | 5.52E+00  | 1.55E+00    | 5.10E-03      | 5.30E-01   | 5.30E-01 | 2.95E-03    | 1.55E-01      | high                    |
| MDMA             | <LOQ      | <LOQ        | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | high                    |
|                  | <LOQ      | <LOQ        | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | high                    |
|                  | 9.15E+00  | 4.24E-02    | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | low                     |
| lidocaine        | <LOQ      | <LOQ        | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | low                     |
|                  | 1.62E-02  | 3.55E+00    | 1.36E+03      | 1.09E+01   | 1.50E-01 | 1.62E-02    | 1.62E-02      | low                     |
|                  | 4.22E+01  | 5.81E+00    | 6.98E-04      | 2.24E+00   | 9.72E-04 | 5.75E-04    | 1.62E-02      | low                     |
| carbasazepine    | 6.88E+01  | 2.72E+01    | 1.95E+03      | 1.35E+01   | 1.22E-02 | 2.61E-03    | 3.79E-03      | low                     |
|                  | 6.88E-03  | 4.63E+01    | 2.50E-03      | 1.39E+01   | 1.45E+01 | 2.41E-03    | 7.75E-03      | negligible               |
|                  | 1.08E-02  | 6.88E-03    | 7.75E-03      | 1.15E+01   | 1.66E+01 | 2.41E-03    | 7.75E-03      | negligible               |
|                  | 6.88E-03  | 6.88E-03    | 1.22E-02      | 1.16E-01   | 1.66E+01 | 2.41E-03    | 7.75E-03      | negligible               |
|                  | 1.08E-02  | 1.09E+00    | 2.15E+00      | 1.36E-01   | 2.41E+01 | 4.09E+00    | <LOQ          | negligible               |
|                  | 1.56E-03  | 1.30E+00    | 2.80E-01      | <LOQ       | <LOQ      | <LOQ        | <LOQ          | negligible               |
|                  | 1.00E-01  | 6.67E-03    | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | <LOQ                    |
|                  | 2.15E-01  | 8.67E-03    | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | <LOQ                    |
|                  | 6.28E+00  | 1.99E-01    | 5.29E+01      | 3.35E+00   | 6.2E-04  | 2.50E+00    | 2.31E+00      | negligible               |
|                  | 1.30E-01  | 1.30E-02    | 3.53E+01      | 3.17E-04   | 3.09E-04 | 1.04E+00    | 4.16E-03      | negligible               |
|                  | 2.00E+01  | 2.44E+00    | 2.44E-01      | 3.83E-03   | 2.98E+02 | 3.83E-03    | 3.83E-03      | low                     |
|                  | 2.00E-01  | <LOQ        | <LOQ          | 2.44E+00   | 2.44E-01 | 2.44E-01    | 2.44E-01      | medium                  |
|                  | 1.30E-01  | 4.16E-05    | <LOQ          | <LOQ       | <LOQ      | <LOQ        | <LOQ          | negligible               |
|                  | 1.29E-01  | 5.94E+00    | 2.28E-03      | <LOQ       | <LOQ      | <LOQ        | <LOQ          | negligible               |
| level of risk    |           |             |               |            |           |             |               |                          |
| negligble        |           |             |               |            |           |             |               |                          |
| low              |           |             |               |            |           |             |               |                          |
| medium           |           |             |               |            |           |             |               |                          |
| high             |           |             |               |            |           |             |               |                          |
| negligible       |           |             |               |            |           |             |               |                          |
### Supplementary Table 2 - MEC data (in ng/L), calculated maxRQ, and MAX RQ values of 42 PhACs, as well as risk levels of study area, in the periods investigated (LOQ = limit of quantitation)

| Substance   | maxRQ | MEC 1 | MEC 2 | MEC 3 | MEC 4 | MEC 5 | MEC 6 | MEC 7 | MEC 8 | MEC 9 | MAX RQ | Level |
|-------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|-------|
| naproxen    | <LOQ  | -     | 2.19E+00 | 1.45E-04 | <LOQ  | -     | <LOQ  | -     | <LOQ  | -     | 2.77E+01 | 1.83E-03 | negligible |
| progesterone| 9.60E-04 | 1.31E-03 | 1.31E-00 | 1.79E-03 | <LOQ  | 1.13E+00 | 1.54E-03 | <LOQ  | -     | <LOQ  | 1.79E-03 | negligible |
| alprazolam  | 1.40E-04 | 2.76E-04 | 8.80E-01 | 1.73E-03 | 3.30E-01 | 6.50E-04 | 7.05E-01 | 1.39E-03 | <LOQ  | -     | 4.52E-01 | 8.89E-04 | 1.73E-03 | negligible |
| tetracaine  | 2.53E+00 | 2.90E-04 | 1.44E+01 | 1.66E-03 | 1.18E+01 | 1.36E-03 | 1.20E+01 | 1.38E-03 | 5.94E-01 | 6.81E-05 | 1.25E+00 | 1.44E-04 | 1.33E+00 | 1.53E-04 | 1.66E-03 | negligible |
| nordiazepam | 1.39E-04 | 1.58E-03 | <LOQ  | -     | <LOQ  | -     | <LOQ  | -     | <LOQ  | -     | 1.58E-03 | negligible |
| zolpidem    | <LOQ  | -     | 4.10E-01 | 1.54E-04 | <LOQ  | -     | 2.20E+00 | 8.28E-04 | <LOQ  | -     | 8.28E-04 | negligible |
| testosterone| <LOQ  | -     | <LOQ  | -     | 1.09E+00 | 7.62E-04 | 1.09E-03 | <LOQ  | -     | <LOQ  | 7.62E-04 | negligible |
| verapamil   | 5.30E-01 | 1.47E-05 | 2.71E+01 | 7.54E-04 | <LOQ  | -     | 1.43E+00 | 3.96E-05 | <LOQ  | -     | 3.96E-05 | negligible |
| losartan    | <LOQ  | -     | <LOQ  | -     | 8.45E-01 | 4.45E-04 | <LOQ  | -     | <LOQ  | -     | 2.18E-01 | 1.14E-04 | 4.45E-04 | negligible |
| clozapine   | 5.40E-01 | 3.68E-04 | 5.50E-01 | 3.75E-04 | <LOQ  | -     | <LOQ  | -     | <LOQ  | -     | 5.54E-01 | 3.77E-04 | 3.77E-04 | negligible |
| diazepam    | <LOQ  | -     | <LOQ  | -     | 2.50E-01 | 1.76E-04 | 9.62E-05 | <LOQ  | -     | <LOQ  | 1.76E-04 | negligible |
| olanzapine  | <LOQ  | -     | <LOQ  | -     | 1.18E+00 | 8.36E-05 | <LOQ  | -     | <LOQ  | -     | 8.36E-05 | negligible |
| metoprolol  | <LOQ  | -     | 5.08E+00 | 8.26E-05 | <LOQ  | -     | 1.17E+00 | 1.90E-05 | 2.64E-01 | 4.28E-06 | <LOQ  | 1.25E+00 | 2.04E-05 | 8.26E-05 | negligible |
| barbital    | <LOQ  | -     | <LOQ  | -     | <LOQ  | -     | 9.48E+01 | 8.16E-05 | <LOQ  | -     | 8.16E-05 | negligible |
| cocaine     | <LOQ  | -     | 1.60E-01 | 7.01E-05 | <LOQ  | -     | <LOQ  | -     | <LOQ  | -     | 7.01E-05 | negligible |
| mirtazapine | 5.10E-01 | 1.59E-05 | 5.30E-01 | 1.66E-05 | 1.90E-01 | 5.94E-06 | <LOQ  | -     | <LOQ  | -     | 2.34E-01 | 7.31E-06 | 7.65E-01 | 2.39E-05 | 2.39E-05 | negligible |
| perindopril | 1.24E+00 | 1.25E-06 | 1.77E+01 | 1.79E-05 | 3.79E+00 | 3.83E-06 | 2.11E+00 | 2.13E-06 | <LOQ  | -     | 6.15E+00 | 6.21E-06 | 1.79E-05 | negligible |
| methadone   | <LOQ  | -     | <LOQ  | -     | 6.40E-01 | 1.68E-05 | <LOQ  | -     | <LOQ  | -     | 1.68E-05 | negligible |
| quetiapine  | 1.20E-03 | 1.20E-05 | 1.10E-01 | 1.10E-05 | <LOQ  | -     | <LOQ  | -     | <LOQ  | -     | 1.20E-05 | negligible |
| lamotrigine | 8.57E+00 | 5.71E-08 | 1.62E+02 | 1.08E-06 | 2.21E+01 | 1.47E-07 | 3.34E+01 | 2.23E-07 | <LOQ  | -     | 5.54E-01 | 3.69E-07 | 1.08E-06 | negligible |
| benzoylecgonine | <LOQ  | -     | 2.33E+00 | 3.42E-07 | <LOQ  | -     | <LOQ  | -     | <LOQ  | -     | 3.42E-07 | negligible |
Supplementary Fig. 2 - SSD curves of caffeine (A) and estradiol (B) derived from CAFE database with search conditions. HC5 – represents hazard concentration in case of 5% of the species in the SSD exhibit an effect.